Monday through Friday.
The Leukemia & Lymphoma Society (LLS) s the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. With more than $285 million currently committed to multi-year research grants and private sector alliances, the research budget is equivalent to that of a mid-sized pharmaceutical company. LLS has the size and scope to fund research on a scale that makes progress happen.
As there are no means of preventing or screening for most blood cancers, we focus on finding cures. In our 66-year history, LLS has invested more than $1 billion in research to advance lifesaving treatments and cures. We serve as a catalyst for collaboration, initiating strategic partnerships with academic centers and biotechnology companies to rapidly turn promising research into critically needed therapies. LLS exists to find cures and ensure access to treatments for blood cancer patients.
With no profit incentives or market share goals, LLS funds research based on unmet needs of blood cancer patients. The fatality rate is second only to lung cancer; and Leukemia is the leading cause of cancer death for children. We measure success in lives saved. Blood
cancer research can be the gateway to studying all types of cancers, with nearly half the cancer-fighting drugs approved by the FDA from 2000 to 2012 having been approved to treat patients with blood cancers. Our goal is a world without blood cancers.